%0 Journal Article
%T Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?
%A Ayala-de Miguel C
%A Jiménez-Castro J
%A Sánchez-Vegas A
%A Díaz-López S
%A Chaves-Conde M
%J Crit Rev Oncol Hematol
%V 202
%N 0
%D 2024 Oct 21
%M 39043356
%F 6.625
%R 10.1016/j.critrevonc.2024.104454
%X Colorectal cancer remains the third most common cancer worldwide and the second cause of cancer-related death. Treatment advances and precision oncological medicine for these tumours have been stalled in comparison to those for other common tumours such as lung and breast cancer. However, the recent publication of the SUNLIGHT trial results with the trifluridine/tipiracil (TAS-102)-bevacizumab combination and the irruption of new molecular targets with guided treatments have opened new possibilities in third-line metastatic colorectal cancer management. Anti-EGFR rechallenge, anti-HER2 targeted therapies or the promising results of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), are some of the available options that may modify what is presumably third-line colorectal treatment. Hereby, we present the evidence of the different treatment options in third-line colorectal cancer and beyond, as well as the possibilities of sequencing them.